Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
暂无分享,去创建一个
M. Bartholomä | S. Maus | S. Ezziddin | A. Sabet | M. Ries | F. Khreish | M. Saar | F. Rosar | Niklas Kochems | Fadi Khreish